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Abstract
Background: Oxygen desaturation during exercise is common in people with chronic obstructive pulmonary
disease (COPD). The aim of the study is to determine, in people with COPD who desaturate during exercise,
whether supplemental oxygen during an eight-week exercise training program is more effective than medical air
(sham intervention) in improving exercise capacity and health-related quality of life both at the completion of
training and at six-month follow up.
Methods/Design: This is a multi-centre randomised controlled trial with concealed allocation, blinding of
participants, exercise trainers and assessors, and intention-to-treat analysis. 110 people with chronic obstructive
pulmonary disease who demonstrate oxygen desaturation lower than 90 % during the six-minute walk test will be
recruited from pulmonary rehabilitation programs in seven teaching hospitals in Australia. People with chronic
obstructive pulmonary disease on long term oxygen therapy will be excluded. After confirmation of eligibility and
baseline assessment, participants will be randomised to receive either supplemental oxygen or medical air during
an eight-week supervised treadmill and cycle exercise training program, three times per week for eight weeks, in
hospital outpatient settings. Primary outcome measures will be endurance walking capacity assessed by the
endurance shuttle walk test and health-related quality of life assessed by the Chronic Respiratory Disease
Questionnaire. Secondary outcomes will include peak walking capacity measured by the incremental shuttle walk
test, dyspnoea via the Dyspnoea-12 questionnaire and physical activity levels measured over seven days using an
activity monitor. All outcomes will be measured at baseline, completion of training and at six-month follow up.
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Discussion: Exercise training is an essential component of pulmonary rehabilitation for people with COPD. This
study will determine whether supplemental oxygen during exercise training is more effective than medical air in
improving exercise capacity and health-related quality of life in people with COPD who desaturate during exercise.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000395831, 5th Jan,2012
Keywords: Chronic obstructive pulmonary disease (COPD), Exercise training, Oxygen desaturation, Supplemental
oxygen
Background
Pulmonary rehabilitation is an important component of
the management of people with chronic obstructive pul-
monary disease (COPD) with strong evidence of efficacy
[1]. Clinically significant improvements in exercise cap-
acity, symptoms of breathlessness, fatigue and health-
related quality of life (HRQoL) are consistently docu-
mented in randomised controlled trials of pulmonary re-
habilitation [1]. The magnitude of benefit in exercise
capacity may be dependent on the intensity of exercise
training. In people with COPD, there is some evidence to
suggest that training at higher intensities confers greater
physiological changes that promote improved exercise cap-
acity [2] and therefore high intensity exercise training is
recommended in pulmonary rehabilitation programs [3].
Exercise-induced oxygen desaturation is common
among people with COPD, with 47 % of those referred
to pulmonary rehabilitation demonstrating a decrease in
oxygen saturation to less than 90 % during a six-minute
walk test (6MWT) [4]. Exercise-induced desaturation
may compromise the intensity of training since those
who desaturate often cannot tolerate high intensity
exercise [3] and healthcare professionals may strive to
minimise exercise-induced desaturation by decreasing
training intensity and/or imposing mandatory rests.
This reduction in exercise intensity is likely to limit the
effectiveness of training [2]. Provision of supplemental
oxygen reduces minute ventilation at equivalent work
rates in people with COPD and delays the onset of dy-
namic hyperinflation and the associated dyspnoea [5, 6],
thus augmenting exercise capacity in people with mod-
erate to severe COPD [7]. Therefore, supplemental oxy-
gen may enable higher exercise intensity during an
exercise training program [8].
For these reasons, supplemental oxygen is often used
in pulmonary rehabilitation for people with COPD, es-
pecially in those patients who desaturate during exer-
cise [4]. However, evidence to support the use of
supplemental oxygen during pulmonary rehabilitation in
this patient group is lacking. Since the provision of supple-
mental oxygen during pulmonary rehabilitation requires
trained staff, increases program costs and restricts the lo-
cations in which training can be delivered, strong evidence
to support or refute the use of supplemental oxygen for
those people with COPD who desaturate during exercise
is required.
The primary aim of the study is to determine, in
people with COPD who desaturate during exercise,
whether supplemental oxygen during exercise training is
more effective than medical air (sham intervention) in
improving endurance exercise capacity and HRQoL, at
the completion of exercise training and at six-month
follow-up.
The secondary aim is to determine, in people with
COPD who desaturate during exercise, whether supple-
mental oxygen during exercise training is more effective
than medical air in improving walking capacity, reducing
dyspnoea and increasing levels of daily physical activity,




This study will be a prospective, multi-centre, randomised
controlled trial with concealed allocation, blinding of par-
ticipants, therapists and assessors and with intention-to-
treat analysis.
Participants
People will be eligible for inclusion if they have: a diagnosis
of COPD (post-bronchodilator forced expiratory volume in
one second (FEV1) / forced vital capacity (FVC) ratio of
<0.7; a greater than 10 pack-year smoking history; medic-
ally stable (at least four weeks post an exacerbation); and
evidence of oxygen desaturation to less than 90 % during
the 6MWT performed on room air. Participants with co-
existing cardiac conditions, such as controlled atrial fibril-
lation and controlled heart failure, will be included to en-
sure that the sample population is representative and
reflective of patients currently referred to pulmonary re-
habilitation programs. Informed written consent will be
obtained from all participants and the study has been ap-
proved by the Ethics Committees of all participating sites
(Human Research Ethics Committee of Sydney Local
Health District, South Western Sydney Local Health Dis-
trict, Austin Health, The Prince Charles Hospital and Cur-
tin University). The trial is registered with Australian New
Zealand Trial Registry: ACTRN12612000395831.
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People will be excluded if they are receiving long-term
oxygen therapy, have a resting partial pressure of arterial
oxygen (PaO2) on room air of < 55 mmHg or a partial
pressure of arterial carbon dioxide (PaCO2) of > 50 mmHg,
have participated in any supervised exercise training in
the last 12 months or if they have co-morbidities such as
severe cardiovascular, neurological or musculoskeletal
conditions that are likely to adversely affect performance
during assessments or exercise training.
The flow of participants through the trial will reflect
the recommendations from the Consolidated Standards
of Reporting Trials (CONSORT) guidelines [9] (Fig. 1).
Participants will receive written and verbal information
explaining the study and written consent will be ob-
tained from each participant. Ethics approval to conduct
the study has been obtained from the Ethics Committees
of the seven participating sites.
Recruitment
Participants will be recruited from referrals to pulmonary
rehabilitation programs at the participating sites (Royal
Prince Alfred Hospital, Concord Repatriation General
Hospital, Liverpool Hospital, Sydney; Austin Hospital and
The Alfred Hospital, Melbourne; The Prince Charles Hos-
pital, Queensland; Sir Charles Gairdner Hospital, Perth).
Prior to randomisation participants will undergo screening
tests to ensure eligibility.
Screening tests
Participants will perform two 6MWTs while breathing room
air to ensure that they meet the study criteria related to oxy-
gen desaturation on exertion. Oxygen saturation (SpO2) will
be monitored continuously through the 6MWTs via a finger
probe attached to a portable saturation monitor (RAD-5v
Masimo Corp, Irvine, CA, USA). The nadir SpO2 from the
better 6MWT (i.e. the greatest distance walked) will be used
as the measure of oxygen desaturation.
Additional measures undertaken prior to randomisa-
tion (i.e. baseline) will comprise spirometry, resting lung
volumes, single breath diffusing capacity for carbon
monoxide (DLCO) and PaO2 and PaCO2, whilst breath-
ing room air [10–12].
Fig. 1 Flow of participants through the trial. LTOT = long term oxygen therapy
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Randomisation
Participants who meet the study inclusion criteria and
complete the baseline assessments will be randomly
allocated into one of the two groups: Oxygen Group or
Air Group. Equal numbers of participants will be rando-
mised to each group. Sequence generation will be deter-
mined using a computerised random number generator
with stratification for study site, six-minute walk dis-
tance (6WMD) (≤350 metres vs >350 metres) and level
of nadir SpO2 from the 6MWT (nadir SpO2 between 89-
86 % vs < 86 %). Allocation concealment will be achieved
by the use of a central telephone randomisation system
coordinated through the National Health and Medical
Research Council Clinical Trials Centre at The University
of Sydney. This will ensure that the researchers are
blinded to the sequence generation.
Blinding
Participants, exercise trainers and assessors will be blinded
as to whether the participants are receiving oxygen or med-
ical air. Oxygen concentrators (Air Liquide, Healthcare Pty
Ltd, Australia) will be used for the delivery of supplemental
oxygen to the Oxygen Group. Oxygen concentrators modi-
fied by Air Liquide with Therapeutic Goods Administration
(TGA) approval to deliver medical air only, will be used for
the Air Group. The concentrators for the Oxygen and Air
Groups will be identical and coded by an independent body
(Air Liquide, Healthcare Pty Ltd, Australia). The code to
distinguish which intervention a participant is receiving will
only be available to the randomisation centre.
Experimental intervention
Both the Oxygen and Air Groups will participate in the
same supervised exercise training program. The Oxygen
Group will receive intranasal oxygen at 5 L/min from an
oxygen concentrator during this exercise training pro-
gram. The Air Group will receive intranasal air at 5 L/
min from an oxygen concentrator modified to deliver air
during this exercise training program. The fixed flow
rate of 5 L/min will ensure adequate delivery of gas
through the concentrators for both groups.
Exercise training
Exercise training will consist of supervised treadmill
walking and stationary cycling, performed three times
per week for eight weeks. The training period will be
extended to 10 weeks if training is interrupted by the in-
ability to attend due to illness with the aim of complet-
ing a minimum of 20 sessions. The initial duration of
exercise training will be 30 minutes (20 minutes
treadmill walking and 10 minutes stationary cycling)
and will be progressed up to a total of 40 minutes
(20 minutes treadmill walking and 20 minutes station-
ary cycling) by week three.
The initial exercise intensity for each mode of training
will be standardised across the Oxygen and Air Group.
For the treadmill walking, the initial intensity will be set at
80 % of the participant’s average speed achieved during
the 6MWT (based on the best 6MWT performed at the
screening assessment). For stationary cycling, the initial
intensity will be set at 60 % of the peak work rate esti-
mated using the distance walked in the best 6MWT [13].
Progression of training
Participants will score dyspnoea and rate of perceived ex-
ertion (RPE) after each treadmill and cycle training session
using the modified dyspnoea and RPE 0–10 scales [14,
15]. These scores will be used to guide the progression of
both treadmill and cycle training, with the aim to keep ei-
ther dyspnoea or RPE at a ‘moderate’ to ‘somewhat severe’
level (i.e. a score of 3 to 4).
To progress treadmill training, the walking speed will
be increased once a participant completes three sessions
at the prescribed speed. If the initial walking speed is <
3 km/hr, the speed will be increased by 0.25 km/hr. If
the initial walking speed is >3 km/hr the speed will be
increased by 0.5 km/hr. If the participant reports both
dyspnoea and RPE scores < 3 after a treadmill training
session, the speed for the next training session will be
increased as tolerated. Once the participant has reached
a walking speed of 5 km/hr, the speed will be reduced to
4.5 km/hr and a gradient of 1 to 2 % will be added. The
gradient will be increased by 1 to 2 % after every three
training sessions if symptoms of dyspnoea and RPE
allow (i.e. dyspnoea and RPE scores < 3). If the partici-
pant experiences difficulty achieving a walking speed of
5 km/hr (e.g. unable to walk fast due to short stride
length) and reports dyspnoea or RPE scores < 3, the gra-
dient will be introduced earlier to ensure the exercise in-
tensity is appropriate.
Cycle training will be progressed after six sessions if
the participant reports dyspnoea or RPE scores < 3.The
progression will be an increase in duration of cycle train-
ing by five minutes, to a maximum of 20 minutes. Once
the participant is able to successfully perform three
sessions of cycle training for 20 minutes and if dyspnoea
and RPE scores are < 3, the work rate will be increased
by 5 watts. Thereafter, for the remainder of the training
program, the intensity of the cycle based training will be
increased in 5 watt increments, once a participant
completes three sessions at the prescribed intensity with
dyspnoea and RPE scores <3.
Safety during the exercise training sessions
While oxygen desaturation during exercise has been
shown to be common in people with COPD, a recent
study showed that oxygen desaturation below 80 % dur-
ing a 6MWT only occurred in 26 out of 572 participants
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(i.e. 4.5 %) [16]. In the current study, it is anticipated
that an even smaller proportion will desaturate below
80 % during exercise training as the intensity of exercise
will be less than the peak achieved during the 6MWT.
In addition, half the participants in this study will be allo-
cated to the Oxygen Group and will receive oxygen during
their exercise training sessions, thereby ameliorating any
desaturation. For this reason, the decision has been made
that the trainers will not monitor SpO2 during the training
program. This will ensure that they stay blinded to group
allocation. Nevertheless, to ensure participant safety, SpO2
will be monitored and recorded throughout the training
program by a clinician who is not involved in exercise pre-
scription or progression. A standardised pulse oximeter
(RAD-5v Masimo Corp, Irvine, CA, USA) will be used at
all sites. The pulse oximeter will be hidden from the par-
ticipant and trainer in order to maintain blinding. This
clinician will also be blinded to group allocation and will
not reveal the changes in SpO2 to the trainer unless SpO2
falls below 80 % [17], at which point the participant will
be asked to stop exercising and rest. The participant will
be instructed to recommence exercising when SpO2
returns to 88 %. The clinician will monitor the initial exer-
cise training session and, thereafter, will monitor an entire
training session once a week for the remainder of the
training program.
Participant education
At the end of the exercise training program an education
booklet [18] will be provided and an individualised home
maintenance exercise program will be given to all partici-
pants. All participants will be encouraged to complete the
home exercise program for six months after which they
will return for reassessment. No supplemental oxygen will
be provided for the home program.
Outcome measures
The primary outcomes will be endurance exercise
capacity measured by the endurance shuttle walk test
(ESWT) [19] and HRQoL measured by the Chronic Re-
spiratory Disease Questionnaire (CRQ) [20]. The sec-
ondary outcomes will be peak exercise capacity
measured by the incremental shuttle walk test (ISWT)
[21], level of dyspnoea using the Dyspnoea-12 Question-
naire [22] and physical activity levels measured by a
multi-sensor activity monitor (SenseWear MF, BodyMe-
dia, Pittsburgh USA) worn for seven days.
An assessor who is blinded to group allocation will
carry out all outcome measures at baseline, at the com-
pletion of exercise training and six months following
completion of the exercise training program. All the ex-
ercise outcome measures at each time point, will be per-
formed with the participant breathing room air.
Primary outcomes
Endurance exercise capacity: Endurance exercise cap-
acity will be measured by the ESWT, performed accord-
ing to a published protocols [19]. The ESWT is an
externally paced constant work rate test which is per-
formed at a walking speed equivalent to 85 % of the par-
ticipant’s peak speed achieved on the incremental shuttle
walk test (ISWT) [23]. Participants will be asked to walk
for as long as possible, back and forth along a 10 metre
shuttle course, in time to a pre-recorded auditory signal.
Dyspnoea and RPE will be recorded each minute during
the test and at the beginning and end of the test using
the modified Borg 0–10 Scale [14, 15]. Heart rate and
SpO2 will be monitored continuously using a portable
saturation monitor (RAD-5v Masimo Corp, Irvine, CA,
USA) and recorded each minute. At the end of the test,
each participant will be asked to identify the main rea-
son for stopping the test.
The ESWT will be performed twice at all assessment
time points. Participants will rest for at least 30 minutes
between tests or until SpO2, dyspnoea and heart rate
have returned to resting levels. Due to the ceiling effect
of 20 minutes in the ESWT [19], the ESWT protocol
will be modified so that if the participant completes
more than 10 minutes in the first baseline ESWT, the
test will be stopped and repeated at a higher level. The
goal is to have each participant's baseline ESWT time
between five and 10 minutes. This will allow the test
to demonstrate improvement without reaching the
20 minute test termination at assessments after train-
ing. The walking speed for repeat testing of the
ESWT after exercise training and at six-month follow-
up will remain the same as that of the participant’s
highest level baseline test. The greater time walked in
the ESWT at each assessment time point will be re-
corded for analysis. The minimal important difference
for the ESWT following ground walking training in
people with COPD is 156 seconds [24].
HRQoL: The interviewer-administered version of the
CRQ [20] will be used to measure disease-specific
HRQoL. The questionnaire consists of 20 questions which
are grouped into one of four domains: dyspnoea (5 ques-
tions), fatigue (4 questions), emotional functioning
(7 questions) and mastery (4 questions). Each question is
scored from one to seven, with a higher score indicating a
better health status. A total score, as well as individual
domain scores, will be calculated. The CRQ has been
shown to be a reliable and valid tool for measuring
HRQoL in people with chronic respiratory disease [20]. A
change of 0.5 in the mean score per domain (calculated by
dividing the overall score by the number of questions) has
been shown to be associated with a minimal important
difference in health status [25]. This means that a minimal
important difference would be 2.5 for dyspnoea, 2
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for fatigue, 3.5 for emotional function, 2 for mastery, and
10 for the total CRQ score.
Secondary outcomes
Peak exercise capacity will be measured using the ISWT
which is an incremental, externally paced, symptom-
limited test with walking speed increasing each minute
[26]. The participant will be asked to walk back and forth
along the 10 metre shuttle course in time with the pre-
recorded auditory signals. There are 12 one-minute levels,
with each level requiring the participant to perform suc-
cessively more shuttles in each minute. Dyspnoea and
RPE will be recorded at the beginning and end of the test
and each minute during the test using the modified Borg
0–10 Scale [14, 15]. Heart rate and SpO2 will be moni-
tored continuously using a portable saturation monitor
(RAD-5v Masimo Corp, Irvine, CA, USA) and recorded
each minute. The test is terminated when the participant
chooses to stop or when, on two consecutive auditory sig-
nals, the participant is more than one metre from the clos-
est cone [26]. At the end of the test, participants will be
asked to identify the main reason for stopping.
The ISWT will be performed twice at baseline and at
subsequent assessments to account for a learning effect
[26] and the greater distance recorded for analysis. Partici-
pants will rest for at least 30 minutes between tests or until
SpO2, dyspnoea and heart rate have returned to resting
levels. The minimal important difference for the ISWT for
pulmonary rehabilitation is 47.5 metres (95 % confidence
intervals 38.6 to 56.5 metres) [27].
Dyspnoea will be measured by the Dyspnoea-12 ques-
tionnaire [22]. The Dyspnoea-12 questionnaire consists
of 12 descriptor items on a scale of none (zero point),
mild (one point), moderate (two points), or severe (three
points). It provides an overall score for severity of
dyspnoea that incorporates seven items pertaining to the
quality of the sensation of dyspnoea and five items
pertaining to the emotional response to the sensation of
dyspnoea. The time reference period for “these days”
captures the current level of dyspnoea experienced by
the participants as opposed to specifically on the day of
the test or in response to a specific activity. The total
score for the Dyspnoea-12 questionnaire ranges from 0
to 36, with higher scores corresponding to greater sever-
ity of dyspnoea.
Physical activity will be measured by a multi-sensor
activity monitor (SenseWear MF, BodyMedia, Pittsburgh,
USA). This device provides information on activity
intensity via energy expenditure, duration of levels of en-
ergy expenditure and step count. The activity monitor
will be worn continuously over a seven-day period at
baseline, at the completion of exercise training and at
the six-month follow-up assessment. Minimum wear
time will be set at three days for at least 20 hours per day.
This device is well tolerated in people with COPD [28]
and has been shown to provide a reliable and valid meas-
ure of physical activity in people with COPD [29, 30].
Additional measures
At each assessment time point, spirometry (EasyOne
handheld Spirometer, ndd Medical Technologies,
Chelmsford, MA) will be performed to determine
whether the participant’s lung function remains stable
during the study period.
Data analysis
For all outcome measures the primary analyses will be via
intention-to-treat and will be conducted by a statistician
who has not been involved in the study and is unaware of
group allocation. Data will be analysed using linear mixed
models or analysis of covariance (ANCOVA) if there are
between group differences at baseline. Uncertainty regard-
ing the size of the mean between group differences will be
quantified with 95 % confidence intervals.
Sample size
A total of 110 participants (55 per group) will be recruited
to ensure that 88 participants complete the study, allowing
for a 20 % loss to follow-up. Regarding primary outcomes,
88 participants will be sufficient to provide 80 % power to
detect as significant, at the (two-sided) 5 % level, a mini-
mum 156 second difference [24] in the mean ESWT time
between the Oxygen Group and the Air Group. This as-
sumes a standard deviation of 250 seconds for the ESWT,
as has been previously reported when comparing two
modes of exercise training in COPD [31]. For the HRQoL
outcome, 88 participants will be sufficient to provide 80 %
power to detect as significant, at the (two-sided) 5 % level,
a minimum 10 point difference [32] in the mean CRQ
total score between the groups, assuming a standard devi-
ation (SD) of 17 points [33].
Regarding secondary outcomes, 82 participants will
be sufficient to provide 80 % power to detect as signifi-
cant, at the (two-sided) 5 % level, a minimum of 2.5
point difference (a change of 0.5 point per question for
a total of five questions in the dyspnoea domain)
between groups in the mean score of the dyspnoea do-
main of the CRQ, assuming a SD of 4.0 [34]. For the
physical activity outcome, 82 participants will be suffi-
cient to provide 80 % power to detect as significant, at
the (two-sided) 5 % level, a minimum of 1845 step dif-
ference in the mean steps per day between the groups,
assuming a SD of 2968 steps for people with moderate
to severe COPD [35].
Discussion
The primary aim of this study is to determine if supple-
mental oxygen is more effective than medical air (sham
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intervention) during exercise training in improving en-
durance exercise capacity and HRQoL for people with
COPD who desaturate during exercise. We hypothesise
that: i) exercise training with supplemental oxygen will in-
crease endurance exercise capacity and HRQoL more than
exercise training with medical air; and ii) the difference in
exercise capacity between groups will be maintained at a
follow-up assessment undertaken six months following
completion of the training period.
Evidence to support the use of supplemental oxygen
during exercise training in people with COPD who de-
saturate during exercise is lacking. Three previous ran-
domised controlled trials have evaluated the effects of
supplemental oxygen during a program of supervised
exercise training in people with COPD who experience
oxygen desaturation on exertion and failed to show be-
tween group differences [36–38]. These trials had design
limitations with lack of participant and/or investigator
blinding to group allocation and small sample sizes (≤12
per group). Furthermore, as the studies did not report the
progression of training intensity it is not clear whether the
participants in the intervention groups were able to
achieve a higher training intensity using supplemental
oxygen.
In contrast with these earlier studies, a small study by
Emtner et al. [8] used a double-blind placebo controlled
randomised study design and showed that the group that
received supplemental oxygen (n = 14) achieved higher
training intensities and had significantly greater exercise
endurance time compared with the group that trained
using compressed air (n = 15). However, this study re-
cruited people with moderate to severe COPD, who did
not desaturate during exercise, therefore, the results can-
not be applied to those who would typically be considered
for supplemental oxygen during pulmonary rehabilitation
programs. In addition, the study used cycle-based training
exclusively, whereas most pulmonary rehabilitation pro-
grams in Australia [39-43 ] and other countries [44, 45]
use both walking and cycle-based exercise. This is an im-
portant difference as the physiological responses to
cycle and walking-based exercise differs significantly
in people with COPD [46, 47]. Specifically, people
with COPD demonstrate more profound oxygen de-
saturation during walking-based exercise compared to
cycle-based exercise [47, 48] and therefore the effect
of supplemental oxygen may differ between these two
exercise modalities. Since the study by Emtner et al. [8]
was based exclusively on both exercise training and testing
using a cycle ergometer it remains unclear if supplemental
oxygen confers benefits in terms of walking-based exercise
capacity in those who desaturate during walking exercise.
Walking is a common activity of daily living and thus
gains in walking capacity are more likely to be important
to people with COPD.
Oxygen desaturation < 90 % during exercise affects
47 % of people with COPD referred to pulmonary
rehabilitation programs in Australia [16, 48]. Previous
work has shown that those who desaturate during
walking-based exercise gain improvement in exercise
capacity, measured as six-minute walk distance
(6MWD), with acute administration of supplemental
oxygen [49]. Specifically, in those who desaturated ≥ 5 %
to < 90 % during a 6MWT, supplemental oxygen in-
creased 6MWD (i.e. an increase from 391 to 450 metres;
p < 0.02) [49]. In contrast, no change in 6MWD was ob-
served in response to supplemental oxygen in those who
did not meet these criteria for desaturation [49]. The
capacity of supplemental oxygen to confer gains in
6MWD only in those who desaturate may relate to its
amelioration of the adverse pulmonary haemodynamics
associated with exercise-induced hypoxaemia [50]. If
supplemental oxygen during exercise training in people
who desaturate is shown to be an effective intervention
to improve exercise capacity when exercising without
oxygen as well as to improve HRQoL, it has the capacity
to enhance the outcomes of exercise training for nearly
half of all people with COPD.
This proposed study will be the first multi-centre,
double-blind randomised trial investigating the role of
supplemental oxygen in optimising training intensity and
maximising the benefits gained from pulmonary rehabili-
tation in people with COPD who experience oxygen de-
saturation during walking. The recruitment of participants
from pulmonary rehabilitation programs across Australia
will ensure that the study is sufficiently powered to detect
any between group differences. In addition, the rando-
mised allocation of participants and the blinding of the
participants, exercise trainers and assessors will limit bias
and contribute to the high quality assessment of clinical
outcomes.
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